MedTrace Logo

SIRT With Tremelimumab and Durvalumab for Resectable HCC

NCT05701488 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-09-02

No results posted yet for this study

Summary

The goal of this research study is to evaluate the safety and tolerability of tremelimumab and durvalumab with or without Selective Internal Yttrium-90 Radioembolization (SIRT) in participants with resectable hepatocellular carcinoma (HCC) who will undergo liver surgery.

The names of the interventions involved in this study are:

* Durvalumab (a type of immunotherapy)
* Tremelimumab (a type of immunotherapy)
* Selective Internal Yttrium-90 Radioembolization (SIRT) (a type of radiation microsphere bead)

Conditions

Interventions

DRUG

Durvalumab

Intravenous infusion

DRUG

Tremelimumab

Intravenous infusion

DEVICE

SIRT

SIR (Selective Internal Radiation) Sphere resin microspheres, radioactive particles delivered via injection into an artery.

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Sirtex Medical

    collaborator INDUSTRY

  • Jiping Wang, MD, PhD

    lead OTHER

Principal Investigators

  • Jiping Wang, MD, PhD · Dana-Farber Cancer Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-21
Primary Completion
2026-10-01
Completion
2026-10-01
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05701488 on ClinicalTrials.gov